Skip to Content
Søk Menu

R/R AML: The benefit of intensive remission induction chemotherapy prior to allogeneic hematopoietic cell transplantation

The ASAP study is the first randomized controlled trial to question the benefits of intensive remission induction chemotherapy prior to allogeneic hematopoietic cell transplantation for patients with relapsed or refractory AML. Hear the results here, presented by Johannes Schetelig directly from ASH22 in New Orleans.
Johannes Schetelig

Få tilgang

Hvis du er lege, sykepleier eller annen helsepersonell, kan du få tilgang til hele artikkelen ved å opprette en profil på BestPractice Nordic.

Relatert innhold

Gunnar Juliusson

Swedish Result for Cytarabine Treatment of Secondary AML is Better than the Register Studies

/ Gunnar Juliusson
AML Play the Video 07:05
Hanna Duàn

Genomic Subtypes of AML Determines Sensitivity to NK Cell Cytotoxicity

/ Hanna Duàn
AMLASH24 Play the Video 2:36
Gunnar Juliusson

Cytarabine Dose Intensification Improves Survival in Older Patients with AML

/ Gunnar Juliusson
AML Play the Video 08:21

The Development of New Treatment Options within AML Is Slower Than in Other Disease Areas within Hematology

/ BestPractice Nordic
AMLEHA24
Nikolaj Nitschke

Functional Characterization for Germline Variants in Patients with MDS and AML

/ Nikolaj Juul Nitschke
AMLEHA24 Play the Video 03:17

Drug Sensitivity Screening to Guide Clinical Decisions for Hematologic Cancers

/ Sigrid S. Skånland
AMLCLL
Jad Othman

MRD Status in NPM1 Mutated AML Should Be a Part of the Selection of Patients for Transplant in First Remission

/ Jad Othman
AMLASH23 Play the Video 03:32

ASH 2023: Oral Decitabine-Cedazuridine Tablet Shows Promise for AML Treatment in Phase III Study

/ BestPractice Nordic
AMLASH23
Sergio Giralt

In the Era of Personalized Treatment and Targeted Therapies

/ Sergio Giralt
AMLASH23 Play the Video 2:46
Back to top